Sun, Nov 23, 2014, 5:54 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Aegerion Pharmaceuticals, Inc. (AEGR) Message Board

  • jetmanbash jetmanbash Apr 16, 2011 9:53 AM Flag

    Decreased HDL and increased intestinal fat, maybe a bad combo:

    This is just one issue that the FDA may latch onto and require more studies on. Here's something to think about. Also note that the CEO when he talks about the competitor never notes that the competitor raises HDL about 10% while their drug the MTTP inhibitor lowers it:


    HDL and Colorectal Cancer Risk

    HDL levels were inversely associated with colon cancer risk but showed no association with rectal cancer risk.

    Small studies have shown an inverse association between serum levels of HDL and risk for colorectal cancer. The current investigation — a nested case-control study within the European Prospective Investigation into Cancer and Nutrition — is the largest yet to address this issue.

    The study cohort, drawn from 10 western European countries, included more than 520,000 participants who completed dietary and lifestyle questionnaires, had their anthropomorphic measurements recorded, and donated blood samples for future analysis. A total of 1238 participants who developed colorectal cancer after enrollment were matched with controls —1238 cancer-free participants — by age, sex, study center, follow-up time, and details at blood collection (time, patient age, fasting status).

    Serum HDL concentration was inversely associated with risk for colon cancer but not with risk for rectal cancer. The relative risk for each one-standard-deviation (16.6 mg/dL) increase in HDL was 0.78. These results were unaffected by additional adjustments for biomarkers of systemic inflammation, insulin resistance, and oxidative stress, as well as exclusion of the first 2 years of follow-up.

    Comment: The mechanism underlying this inverse association is uncertain. Higher levels of HDL inhibit systemic inflammatory responses, and inflammation might stimulate tumor growth. Of interest and possibly relevant, obesity, metabolic syndrome, and diabetes mellitus are all associated with an increased risk for colorectal cancer, and long-term statin use has been associated with a slight decrease in risk for colorectal cancer. How all these observations are related remains unknown.

    — Douglas K. Rex, MD

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
AEGR
21.37+0.42(+2.00%)Nov 21 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.